Back to Authors

Jain, Deepali

0000-0001-5315-9814

Mayo Clinic

Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.

Citations 3

Dataset for reporting of thymic epithelial tumours: recommendations from the International Collaboration on Cancer Reporting ( ICCR )
Roden, Anja C. , Judge, Meagan , Bakker, Michael A. den , Fang, Wentao , Jain, Deepali , Marx, Alexander , Moreira, André L. , Rajan, Arun , Stroebel, Philipp, Szołkowska, Małgorzata , Ströbel, Philipp , den Bakker, Michael A , Ströbel, Philipp , Cooper, Wendy A , Jain, Deepali

Histopathology | September 18, 2023 | Volume: 83 | Issue: 6 | Pages: 967-980

10.1111/his.15047 Get It

Aims Thymic epithelial tumours (TET), including thymomas and thymic carcinomas and thymic neuroendocrine neoplasms, are malignant neoplasms that can be associated with morbidity and mortality. Recently, an updated version of the World Health Organization (WHO) Classification of Thoracic Tumours 5th Edition, 2021 has been released, which included various changes to the classification of these neoplasms. In addition, in 2017 the Union for International Cancer Control (UICC) / American Joint Committee on Cancer (AJCC) published the 8th Edition Staging Manual which, for the first time, includes a TNM staging that is applicable to thymomas, thymic carcinomas, and thymic neuroendocrine neoplasms. Methods and Results To standardize reporting of resected TET and thymic neuroendocrine neoplasms the accrediting bodies updated their reporting protocols. The International Collaboration on Cancer Reporting (ICCR), which represents a collaboration between various National Associations of Pathology, updated its 2017 histopathology reporting guide on TET and thymic neuroendocrine neoplasms accordingly. This report will highlight important changes in the reporting of TET and thymic neuroendocrine neoplasms based on the 2021 WHO, emphasize the 2017 TNM staging, and also comment on the rigour and various uncertainties for the pathologist when trying to follow that staging. Conclusion The ICCR dataset provides a comprehensive, standardized template for reporting of resected TET and thymic neuroendocrine neoplasms.
Primary Pulmonary Hyalinizing Clear Cell Carcinoma: Case Series With Review of Literature
Thakur, Shilpi , Nambirajan, Aruna , Larsen, Brandon T. , Butt, Yasmeen M. , Roden, Anja C. , Kumar, Sunil, Jain, Deepali , Jain, Deepali

International Journal of Surgical Pathology | December 14, 2022 | Volume: 31 | Issue: 7 | Pages: 1187-1194

10.1177/10668969221137516 Get It

Background: Hyalinizing clear cell carcinomas of tracheobronchial origin are very rare salivary gland type tumors accounting for less than 1% of lung tumors with only 13 cases reported to date. Their radiological features, morphological spectrum, and molecular features are not well described. Aim: To perform a clinicopathological analysis of primary pulmonary hyalinizing clear cell carcinomas. Method: A retrospective search of primary pulmonary hyalinizing clear cell carcinomas was conducted from authors’ institutions and the clinicopathological features including details of molecular testing were analyzed. Results: Five primary pulmonary hyalinizing clear cell carcinomas were identified. The mean patient age at diagnosis was 48.2 years (range: 33-64 years). Three patients were women. All patients were nonsmokers and 3 were symptomatic; 2 were detected incidentally during health screening. The tumors were located in the main lobar bronchi ranging from 1.3 to 4.9 cm in maximum dimension. Microscopy showed cords and nests of at least, focally clear tumor cells. Mucin cysts lacking goblet cells were seen. All tumors were uniformly positive for p40, p63, AE1/AE3, keratin 7, and epithelial membrane antigen but negative for TTF1, KIT, neuroendocrine markers, and other myoepithelial markers. All cases showed Ewing sarcoma breakpoint region 1 ( EWSR1) gene rearrangement. Perineural invasion and lymph node metastases were detected in patient 5. Two patients with available follow-up data were recurrence-free until 4 years (patient 1) and 9 months (patient 5) after resection. Conclusion: The present series adds to the scant available literature on primary pulmonary hyalinizing clear cell carcinomas highlighting the characteristic histomorphology, immunoprofiles, and benign outcomes of these rare tumors.
EWSR1 translocation in primary hyalinising clear cell carcinoma of the thymus
Porubský, Štefan , Rudolph, Birgit, Rückert, Jens‐Carsten, Küffer, Stefan , Roden, Anja C. , Jain, Deepali , Tousseyn, Thomas , Veer, Hans Van , Antonicelli, Alberto , Kuo, Tseng‐tong, Rosaí, Juan, Marx, Alexander , (ITMIG), The International Thymic Malignancy Interest Group, Roden, Anja C , Jain, Deepali , Marx, Alexander , Ströbel, Philipp , Huang, James , (ITMIG), The International Thymic Malignancy Interest Group

Histopathology | May 3, 2019 | Volume: 75 | Issue: 3 | Pages: 431-436

10.1111/his.13890 Get It

AimsIn thymic carcinomas, focal clear cell change is a frequent finding. In addition to a prominent, diffuse clear cell morphology, some of these carcinomas show an exuberant hyalinised extracellular matrix, and therefore probably represent a separate entity. However, a characteristic genomic alteration remains elusive. We hypothesised that, analogous to hyalinising clear cell carcinomas of the salivary gland, hyalinising clear cell carcinomas of the thymus might also harbour EWSR1 translocations.Methods and resultsWe identified nine archived cases of thymic carcinoma with focal clear cell features and two cases that showed remarkable hyalinised stroma and prominent, diffuse clear cell morphology. These two cases expressed p40 and were negative for Pax8, CD5, and CD117. Programmed death‐ligand 1 was highly positive in one case (70%), and negative in the other one. EWSR1 translocation was identified in both cases of hyalinising clear cell carcinoma, and was absent in all nine carcinomas that showed clear cell features without substantial hyalinisation. In one of the EWSR1‐translocated cases, a fusion between exon 13 and exon 6 of EWSR1 and ATF1, respectively was identified by next‐generation sequencing.ConclusionsThese findings suggest that the EWSR1 translocation and possibly the EWSR1–ATF1 fusion might be unifying genomic alterations for thymic clear cell carcinomas with prominent hyalinised stroma, for which we propose the term ‘hyalinising clear cell carcinoma of the thymus’. Because the immunophenotype is unspecific, testing for the EWSR1 translocation might be helpful in discriminating this entity from other thymic neoplasms or metastases, in particular those with clear cell change.